Quarterly ResultMay 13, 2026, 04:07 PM
Eledon Achieves 100% Insulin Independence in T1D Study; FDA Orphan Drug
AI Summary
Eledon Pharmaceuticals reported its Q1 2026 operating and financial results, highlighting significant progress in its tegoprubart program. Key achievements include 100% insulin independence in 10 type 1 diabetes patients following islet transplantation in an investigator-led study, and FDA Orphan Drug designation for tegoprubart in liver transplantation. The company ended the quarter with $111.1 million in cash, cash equivalents, and short-term investments, expecting to fund operations into Q2 2027, despite a net loss of $39.0 million.
Key Highlights
- 100% insulin independence achieved in 10 type 1 diabetes patients treated with tegoprubart post-islet transplantation.
- FDA granted Orphan Drug designation to tegoprubart for preventing allograft rejection in liver transplantation.
- Cash, cash equivalents and short-term investments totaled $111.1 million as of March 31, 2026.
- Company expects current cash to fund operations into Q2 2027.
- Research and development expenses increased to $17.2 million in Q1 2026 from $13.5 million in Q1 2025.
- Net loss for Q1 2026 was $39.0 million, or $0.33 per share, compared to $6.5 million in Q1 2025.
- Upcoming milestones include FDA guidance for Phase 3 kidney transplantation trial and new clinical trial initiations.